CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: DNA repair deficient tumor cells have been shown to accumulate high levels of DNA damage. Consequently, these cells become hyper-dependent on DNA damage response pathways, including the CHK1-kinase-mediated response. These observations suggest that DNA repair deficient tumors should exhibit increased sensitivity to CHK1 inhibition. Here we offer experimental evidence in support of this hypothesis. Results: Using isogenic pairs of cell lines differing only in the Fanconi Anemia (FA) DNA repair pathway, we showed that FA deficient cell lines were hypersensitive to CHK1 silencing by independent siRNAs as well as CHK1 pharmacologic inhibition by Gö6976 and UCN-01. In parallel, an siRNA screen designed to identify gene silencings synthetically lethal with CHK1 inhibition identified genes required for FA pathway function. To confirm these findings in vivo, we demonstrated that whole zebrafish embryos, depleted for FANCD2 by a morpholino approach, were hypersensitive to Gö6976. Silencing of FA genes led to hyper-activation of CHK1 and vice versa. Furthermore, inactivation of CHK1 in FA deficient cell lines caused increased accumulation of DNA strand and chromosomal breakages. These results suggest that the functions subserved by CHK1 and the FA pathway mutually compensate in maintaining genome integrity. As CHK1 inhibition has been under clinical trial in combination with cisplatin, we showed that the FA specific tumoricidal effect of CHK1 inhibition and cisplatin was synergistic. Conclusion: Taken together, these results suggest CHK1 inhibition as a strategy for targeting FA deficient tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“Background Human cancers exhibit genomic instability and heightened drug sensitivity due to underlying defects in DNA repair or cell cycle regulation [1-3].”
BackgroundCell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 1×
“Background Human cancers exhibit genomic instability and heightened drug sensitivity due to underlying defects in DNA repair or cell cycle regulation [1-3].”
BackgroundLiu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway
Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M. S., Timmers, C., Hejna, J., Grompe, M., & D'Andrea, A. D. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00173-3 · Cited by 1,198
Self-citationMDC1 is a mediator of the mammalian DNA damage checkpoint
Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. R., & Elledge, S. J. (2003) · Nature · doi:10.1038/nature01446 · Cited by 874 · cited 1×
“The EUFA130 (FANCE-deficient) and 2008 ovarian tumor line derived have also been previously described [6,40] and were cultured in RPMI medium (Gibco) supplemented with 15% fetal calf serum and 1 μg/ml puromycin.”
MethodEmergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins
Wang, W. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2159 · Cited by 663 · cited 1×
“The thirteen known FA proteins cooperate in this pathway, leading to the monoubiquitination of the FANCD2/FANCI hetero-dimer, activating DNA crosslink repair [4].”
Background
Cited by
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
“FA pathway–deficient cancer cells have a greater requirement for CHK1 function than DNA repair–proficient cells, thereby supporting the presence of a therapeutic window that could be exploited in treating DNA repair–deficient cancers with CHK1 inhibitors, while sparing toxicity in normal, DNA repair–proficient cells (…”
BackgroundSelf-citationHomologous recombination and its regulation
Krejci, L., Altmannova, V., Spirek, M., & Zhao, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks270 · Cited by 641
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Dai, Y., & Grant, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1029 · Cited by 439
Metadata
- Authors
- Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D'Andrea, A.
- Venue
- Molecular Cancer
- Published
- 2009-04-16
- Volume
- 8
- Issue
- 1
- Pages
- 24-24
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2115694409
- Cited by
- 115
- References
- 7
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. https://app.cochat.ai/papers/10.1186/1476-4598-8-24
- The paper
- Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D'Andrea, A. (2009). CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Molecular Cancer. https://doi.org/10.1186/1476-4598-8-24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.